MetLife Investment Management
TRDA icon

MetLife Investment Management’s Entrada Therapeutics TRDA Stock Holding History

MetLife Investment Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Sell
17,655
-147
-0.8% -$1.41K ﹤0.01% 2650
2026
Q1 		$225K Hold
17,802
– – ﹤0.01% 2173
2025
Q4 		$183K Buy
17,802
+10,642
+149% +$89.7K ﹤0.01% 2319
2025
Q3 		$41.5K Sell
7,160
-9,169
-56% -$53.6K ﹤0.01% 2804
2025
Q2 		$110K Hold
16,329
– – ﹤0.01% 2494
2025
Q1 		$148K Hold
16,329
– – ﹤0.01% 2357
2024
Q4 		$282K Buy
16,329
+1,731
+12% +$31.4K ﹤0.01% 2116
2024
Q3 		$233K Hold
14,598
– – ﹤0.01% 2209
2024
Q2 		$208K Buy
14,598
+2,904
+25% +$41.3K ﹤0.01% 2217
2024
Q1 		$166K Hold
11,694
– – ﹤0.01% 2298
2023
Q4 		$176K Hold
11,694
– – ﹤0.01% 2304
2023
Q3 		$185K Hold
11,694
– – ﹤0.01% 2263
2023
Q2 		$177K Buy
+11,694
New +$161K ﹤0.01% 2352

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

MetLife Investment Management's TRDA Position: Q2 2026 in Review

MetLife Investment Management reduced its Entrada Therapeutics (TRDA) stake by 0.83% in Q2 2026, selling an estimated $1.41K and leaving 17,655 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #2650.

MetLife Investment Management first reported a position in TRDA in Q2 2023 and has held it in 13 quarters since. The position peaked at $282K in Q4 2024. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • MetLife Investment Management held 17,655 shares of Entrada Therapeutics worth $130K as of Q2 2026.
  • MetLife Investment Management sold 147 Entrada Therapeutics shares in Q2 2026, an estimated $1.41K.
  • Entrada Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2650 holding.
  • MetLife Investment Management first reported a position in Entrada Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • MetLife Investment Management's Entrada Therapeutics position peaked at $282K in Q4 2024.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.